Ultragenyx announced a programmatic restructuring that will eliminate roughly 130 jobs—about 10% of its workforce—after a year of clinical setbacks and regulatory friction. Management tied the cuts to a drive toward profitability in 2027 and said R&D spending will be reduced and focused on highest‑value programs. The moves follow FDA refusal/requests for more manufacturing data on the company’s gene therapy UX111 for Sanfilippo A and multiple late‑stage trial failures in other programs. Executives warned that manufacturing documentation requests and product‑specific regulatory uncertainty could delay approvals and any associated commercial or voucher revenue, pressuring near‑term financial guidance and prompting the operational reset.